Direct costs of medical attention to Mexican patients with rheumatoid arthritis in a tertiary care center

Clinical and Experimental Rheumatology

Volumn 15, Issue 1, 1997, Pages 75-78

  Ariza Ariza, R ^a,b   Mestanza Peralta, M ^a   Cardiel, M H ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

Author keywords

direct costs; rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT;

ARTICLE; CASE REPORT; CONTROLLED STUDY; DRUG COST; HEALTH CARE COST; HUMAN; MEXICO; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DIRECT SERVICE COSTS; DRUG COSTS; HEMATOLOGIC TESTS; HUMANS; MEXICO; OFFICE VISITS;

EID: 0030976556     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. PRASHKER MJ, MEENAN RF: The total costs of drug therapy for rheumatoid arthritis. A model based on costs of drug, monitoring, and toxicity. Arthritis Rheum 1995; 3: 318-25.
2. BORG G, ALLANDER E, GOOBAR JE: Disease-modifying anti-rheumatic drug therapy. An expensive therapy despite inexpensive drugs. Scand J Rheumatol 1990; 19: 115-21.
3. LIANG MH, FRIES JF: Containing costs in chronic disease: monitoring strategies in the gold therapy of rheumatoid arthritis. J Rheumatol 1978; 5: 241-4.
4. BLOCK SR: The cost of parenteral gold vs oral gold in the long term treatment of rheumatoid arthritis. J Rheumatol 1986; 13: 3.
5. FELTS W, YELIN E: The economic impact of the rheumatic diseases in the United States. J Rheumatol 1989; 16: 867-84.
6. YELIN EH, FELTS W: A summary of the impact of musculoskeletal conditions in the United States. Arthritis Rheum 1990; 33: 750-5.
7. BAKKER C, HIDDING A, VAN DER LINDEN S, VAN DOORSLAER E: Cost effectiveness of group physical therapy compared to individualized therapy for ankylosing spondylitis. A randomized controlled trial. J Rheumatol 1994; 21: 264-8.
8. JACOBS J, KEYSERLING JA, BRITTON M, MORGAN GJ JR, WILKENFELD J, HUTCHINGS HC: The total cost of care and the use of pharmaceutical in the management of rheumatoid arthritis: the Medi-Cal program. J Clin Epidemiol 1988; 41: 215-23.
9. LIANG MH, LARSON M, THOMPSON M: Costs and outcomes in rheumatoid arthritis and osteoarthritis. Arthritis Rheum 1984; 27: 522-29.
10. LUBECK DP: The economic impact of rheumatoid arthritis. In: WOLFE F, PINCUS T (Eds.): Rheumatoid Arthritis: Assessment, Prognosis, Therapy. New York, Marcel Dekker, 1994; 247-59.
11. LUBECK DP, SPITZ PW, FRIES JF: A multicenter study of annual health service utilization and costs in rheumatoid arthritis. Arthritis Rheum 1986; 29: 488-93.
12. MEENAN RF, YELIN EH, HENKE CJ, CURTIS DL, EPSTEIN WV: The costs of rheumatoid arthritis: a patient-oriented study of chronic disease costs. Arthritis Rheum 1978; 21: 827-33.
13. STONE CE: The lifetime costs of rheumatoid arthritis. J Rheumatol 1984; 11: 819-27.
14. ARNETT FC, EDWORTHY S, BLOCK DA, et al.: The 1987 revised ARA criteria of rheumatoid arthritis. Arthritis Rheum 1987; 30: 5-17.
15. PINALS RS: Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981; 24: 1308-15.
16. LUBECK PD: The economic impact of arthritis. Arthritis Care and Research 1995; 8: 304-10.